research:pgx_drug_exposure
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
research:pgx_drug_exposure [2015/03/10 15:03] rkboyce |
research:pgx_drug_exposure [2017/01/15 00:04] (current) rkboyce |
||
|---|---|---|---|
| Line 3: | Line 3: | ||
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** Derive data that large healthcare organizations can combine data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing | + | **Objective:** Derive data that large healthcare organizations can combine with data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing |
| **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. | **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. | ||
| Line 11: | Line 11: | ||
| **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna, Columbia University, Regenstrief Institute, Janssen R&D, AstraZeneca | **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna, Columbia University, Regenstrief Institute, Janssen R&D, AstraZeneca | ||
| - | ** Additional Participants (currently seeking other collaborators):** Patrick Ryan, Jon Duke, George Hripcsak, Abraham G. Hartzema, Christian Reich | + | ** Additional Participants (currently seeking other collaborators):** Patrick Ryan, Jon Duke, George Hripcsak, Abraham G. Hartzema, Christian Reich, Dan Malone |
| **Full Protocol:** [[https://docs.google.com/document/d/1u3AE5DtkEp3m8OcbwkGHtXBVefYGGJ_1RMO3OnqpXiY/edit|Google doc for the protocol]] | **Full Protocol:** [[https://docs.google.com/document/d/1u3AE5DtkEp3m8OcbwkGHtXBVefYGGJ_1RMO3OnqpXiY/edit|Google doc for the protocol]] | ||
| Line 17: | Line 17: | ||
| **Initial Proposal Date:** 2/16/2015 | **Initial Proposal Date:** 2/16/2015 | ||
| - | **Launch Date:** //<fill out once finalized>// | + | **Launch Date:** This was a test research network study and has met its objectives as of 12/1/2016. |
| **Study Closure Date: //<fill out once finalized>//** | **Study Closure Date: //<fill out once finalized>//** | ||
| Line 38: | Line 38: | ||
| ===== Discussion ===== | ===== Discussion ===== | ||
| - | //Post a thread letting everyone know about this new proposed study at [[http://forums.ohdsi.org/c/researchers]]// | + | [[http://forums.ohdsi.org/t/ohdsi-study-3-incidence-of-exposure-to-drugs-for-which-pre-emptive-pharmacogenomic-testing-is-available/387]] |
| + | |||
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
research/pgx_drug_exposure.1425999790.txt.gz · Last modified: 2015/03/10 15:03 by rkboyce
Page Tools
